TCR2 Therapeutics Closes $125 Million B Round for Immunoncology Program

TCR 2 Therapeutics, an Boston immuno-oncology company, closed an oversubscribed $125 million Series B financing. The round was co-led by 6 Dimension Capital, a Boston-Shanghai investor (formed by Frontline and WuXi Healthcare Ventures), along with Curative Ventures of Texas. TCR 2 will use the funds to develop its novel T cell receptor cellular therapies for solid tumors and blood cancers. Specifically, TCR 2 says the funds will be enough to complete human proof-of-concept of two TRuC™-T cell programs. More details.... Share this with colleagues: // //